Used primarily in pharmaceutical research and development, this compound serves as a key intermediate in the synthesis of immunomodulatory drugs, particularly those related to thalidomide analogs. It plays a critical role in targeted protein degradation therapies, including the design of PROTACs (proteolysis-targeting chimeras), which leverage the cell’s ubiquitin-proteasome system to degrade disease-causing proteins. Its structure enables selective binding to E3 ubiquitin ligases, making it valuable in oncology and inflammatory disease research. Additionally, it is employed in studies exploring treatment for multiple myeloma, myelodysplastic syndromes, and other hematological malignancies due to its ability to modulate cereblon activity.